Aisling Capital Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-67,645
| Closed | -$829K | – | 17 |
|
|
2023
Q3 | $829K | Sell |
67,645
-1
| -0% | -$12 | 0.34% | 15 |
|
|
2023
Q2 | $762K | Hold |
67,646
| – | – | 0.37% | 14 |
|
|
2023
Q1 | $490K | Hold |
67,646
| – | – | 0.24% | 13 |
|
|
2022
Q4 | $761K | Hold |
67,646
| – | – | 0.5% | 13 |
|
|
2022
Q3 | $890K | Hold |
67,646
| – | – | 0.59% | 14 |
|
|
2022
Q2 | $854K | Hold |
67,646
| – | – | 0.61% | 16 |
|
|
2022
Q1 | $3.89M | Hold |
67,646
| – | – | 2.1% | 11 |
|
|
2021
Q4 | $8.03M | Hold |
67,646
| – | – | 2.83% | 10 |
|
|
2021
Q3 | $13.4M | Hold |
67,646
| – | – | 2.68% | 7 |
|
|
2021
Q2 | $11.8M | Hold |
67,646
| – | – | 1.88% | 9 |
|
|
2021
Q1 | $13.4M | Hold |
67,646
| – | – | 2.41% | 7 |
|
|
2020
Q4 | $13.3M | Hold |
67,646
| – | – | 2.29% | 7 |
|
|
2020
Q3 | $12M | Hold |
67,646
| – | – | 3.83% | 6 |
|
|
2020
Q2 | $15.6M | Buy |
67,646
+16,000
| +31% | +$3.7M | 5.97% | 4 |
|
|
2020
Q1 | $6.02M | Hold |
51,646
| – | – | 2.62% | 6 |
|
|
2019
Q4 | $9.86M | Hold |
51,646
| – | – | 3.78% | 4 |
|
|
2019
Q3 | $9.93M | Hold |
51,646
| – | – | 5.18% | 6 |
|
|
2019
Q2 | $8.84M | Buy |
51,646
+2,810
| +6% | +$481K | 3.78% | 7 |
|
|
2019
Q1 | $9.83M | Buy |
48,836
+14,091
| +41% | +$2.84M | 7.49% | 6 |
|
|
2018
Q4 | $6.51M | Buy |
+34,745
| New | +$6.51M | 6.85% | 6 |
|